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The cytokine storm is an aggressive immune response characterized by the recruitment of inﬂamma-
tory leukocytes and exaggerated levels of cytokines and chemokines at the site of infection. Here we
review evidence that cytokine storm directly contributes to the morbidity and mortality resulting from
inﬂuenza virus infection and that sphingosine-1-phosphate (S1P) receptor agonists can abort cytokine
storms providing signiﬁcant protection against pathogenic human inﬂuenza viral infections. In
experiments using murine models and the human pathogenic 2009 inﬂuenza viruses, S1P1 receptor
agonist alone reduced deaths from inﬂuenza virus by over 80% as compared to lesser protection (50%)
offered by the antiviral neuraminidase inhibitor oseltamivir. Optimal protection of 96% was achieved by
combined therapy with the S1P1 receptor agonist and oseltamivir. The functional mechanism of S1P
receptor agonist(s) action and the predominant role played by pulmonary endothelial cells as
ampliﬁers of cytokine storm during inﬂuenza infection are described.
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Inﬂuenza virus infections were responsible for nearly 100
million human deaths in the last century. Further, during the
two-year period of 1918–1919, inﬂuenza caused the greatest loss
of life of any infectious disease or medical condition known
(Ahmed et al., 2007; Johnson and Mueller, 2002). During that
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killing 2%. Since that most virulent episode, several inﬂuenza
pandemics have raged, the most recent being the 2009 attack of
swine ﬂu. The 2009 H1N1 inﬂuenza viruses rapidly infected
millions of humans worldwide with an estimated 293,500 deaths
of which 201,200 resulted from respiratory failures and 83,300
cardiovascular insults (Dawood et al., 2012).
Susceptibility or resistance to any viral infection is determined
by a balance between the virulence of the microbe, the resistance
of the host including the aggressiveness of its immune response
against the infecting agent. When the immune response is limited
either because of host genetic or acquired defects, or temporarily
due to lack of normal differentiation of the immune system of
newborns and young children; or decreasing immune responses
of the elderly, the advantage goes to the virus. When infection
occurs in those with a fully developed and competent immune
system, the advantage goes to the host unless the infecting virus
overwhelms the individuals immune system or when the
mechanism that modulates the immune response fails resulting
in an over abundant excessive innate and adaptive immune
response termed ‘‘cytokine storm.’’
Vaccination is employed to protect uninfected reservoirs of
individuals and thereby diminishing the spread of infection.
Antiviral drugs are the primary effective therapy used to diminish
ongoing disease. Antiviral drugs are effective, nevertheless, there
are two compelling limitations to their total efﬁciency and
effectiveness. First, antiviral drugs exert selective pressure on
the virus, resulting in the generation and selection of more ﬁt
viral progeny that per se become resistant to the drug (Nguyen
et al., 2012; Orozovic et al., 2011; Wang et al., 2010). Second, the
pathogenic injury associated with inﬂuenza virus infection results
both from the intrinsic virulence of the virus which is attacked by
anti-inﬂuenza viral drug therapy and the intensity of the immune
response (cytokine storm and viral-induced immunopathologic
tissue damage) which antiviral drugs do not engage. Here, using a
small animal model, we review the evidence from our labora-
tories that cytokine storm alone plays an important and essential
role in causing signiﬁcant tissue injury and mortality following
human pathogenic H1N1 2009 inﬂuenza virus infection. We
document that dampening the host’s immune response against
inﬂuenza virus using speciﬁc immunomodulatory sphingosine-1-
phosphate (S1P) receptor (rec) agonists provide signiﬁcant pro-
tection from mortality over that observed by the neuraminidase
inhibitor oseltamivir. Further, we demonstrate that speciﬁc ago-
nists against S1P1 receptor inhibits innate cellular and cytokine/
chemokine responses that limit virus-induced immunopathologic
injury yet still maintain host control and termination of virus
replication by anti-inﬂuenza virus cytotoxic T cells and neutraliz-
ing antibodies. Utilizing genetic, molecular, and chemical tools we
locate S1P1 receptor on pulmonary endothelial cells, identify
endothelial cells as the central regulators of cytokine storm and show
a mandatory role for interferon type I signaling in this process. Due to
space limitations we do not discuss the role played by the virus and
its genes as virulence factors in H1N1 inﬂuenza virus infection but
point the reader to several publications in this area (Ahmed et al.,
2007; Chou et al., 2011; Fukuyama and Kawaoka, 2011; Hai et al.,
2010; Song et al., 2011; Watanabe et al., 2012).Epidemiologic and experimental evidence for cytokine storm
When accompanied by manifestations of cytokine storm or acute
respiratory distress syndrome, infected individuals display high
mortality with elevated cytokines/chemokines, leukocyte inﬂamma-
tion and edematous lungs during H1N1 1918–1919 and H1N1
2009 pandemic inﬂuenza virus infections in experimental animalmodels (Baskin et al., 2009; Kobasa et al., 2007; Marcelin et al., 2011;
Zhang et al., 2012) and for 2009 infection in humans (Arankalle et al.,
2010; Cheng et al., 2011; Lee et al., 2011). Among the reports of H1N1
2009 infection in humans, that of Arankalle et al. (2010) is illuminat-
ing. These investigators analyzed viral load in lungs of critically ill
patients who died and those who recovered. Both groups showed
roughly equivalent titers of virus. In contrast, mortality correlated
directly with cytokine storm. Thus, the patients who died had higher
cytokine/chemokine levels but equivalent viral titers in pulmonary
samples when compared to patients having a milder infection course
and recovering.
In summary, both experimental studies and human clinical
observations suggested to us that: (1) cytokine storm is associated
with poor outcome in inﬂuenza virus infection, and (2) calming the
host’s aggressive and exaggerated cytokine storm response might
provide the opportunity to decrease morbidity and enhanced survival
to inﬂuenza and likely other acute respiratory diseases like SARS,
Hantavirus infection, and pneumococcal pneumonia that manifest
severe cytokine storm. To test this possibility we turned our attention
to the molecule sphingosine-1-phosphate (S1P) and determined if the
harmful immunologic processes accompanying H1N1 inﬂuenza virus
infection could be modulated by S1P receptors in the lung. If so,
inﬂuenza could be chemically tractable and successfully treated
pharmacologically with therapy directed against the host’s over-
aggressive immune response. Further, this anti-host immune therapy
would be unlikely to generate viral escape variants that is an issue
with antiviral therapy. In addition, such an approach would also
provide new insights into pathogenesis of inﬂuenza viral infections
and may uncover surrogate markers useful for identifying those most
susceptible to inﬂuenza virus infection.Sphingosine-1-phosphate (S1P) properties
S1P is a signaling lipid present at a concentration of 1–3 mM in
plasma and at roughly 100 nM in lymph. The vast majority of S1P
in plasma is bound to high density lipoprotein, leaving a free
concentration between 15 and 45 nM in blood. The metabolism of
S1P is displayed in Fig. 1A. S1P is generated by phosphorylation of
sphingosine by the actions of two intracellular sphingosine
kinases. S1P is degraded either reversible by dephosphorylation
or irreversible by cleavage (reviewed in Rosen et al., 2009, 2007;
Scott, 2011). Physiologically, S1P levels are under tight homeo-
static control and S1P signals through speciﬁc S1P receptors of
which there are ﬁve: S1P receptor 1–5. These ﬁve speciﬁc S1P
receptors are coupled to different G proteins in order to regulate a
variety of downstream signaling pathways that are speciﬁc for
many cells, tissues, and organs (Rosen et al., 2009, 2007; Scott,
2011). S1P and its analogs have been used clinically to induce
sequestration of lymphocytes in secondary lymphoid organs
(Fig. 1B) and by that means limit the migration of effector
lymphocytes to areas where such cells might mediate immuno-
pathologic injury leading to diseases (Rosen et al., 2009, 2007;
Scott, 2011). Indeed, S1P agonist therapy is currently being
prescribed for treatment of multiple sclerosis (MS) and being
considered for treatment of other inﬂammatory disorders.Immune virus-speciﬁc T cell trafﬁcking in vivo during
inﬂuenza virus infection
Inﬁltration of lymphoid cells in pulmonary tissues is one of the
signatures of inﬂuenza virus infection. To study the kinetics of
inﬂuenza virus-speciﬁc CD8 and CD4 T cell entry into the lung
and their anatomic distribution during inﬂuenza infection we
designed an in vivo model taking advantage of the wealth of reagents
Fig. 1. SIP biochemistry and activity in lymphoid organs. Panel A: Synthesis and
regulation of S1P. Panel B: Cartoon of systemic activity of S1P in secondary
lymphoid tissues (see Rosen et al., 2007, 2009 for details). Figure adapted from
Rosen et al. (2009).
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(LCMV). First, a recombinant inﬂuenza virus A/WSN/33 (H1N1 WSN)
was engineered using reverse genetics by our collaborator, Yoshihiro
Kawaoka, to express the immunodominant H-2Db (H-2b MHC class I
background) restricted CD8 T (glycoprotein [GP] aa 33–41) and IAb
(H-2b MHC class II background) CD4 (GP aa 65–77) T cell epitopes for
LCMV into the inﬂuenza neuraminidase (NA) stalk (ﬂu/LCMV)
(Marsolais et al., 2009; Neumann et al., 1999). This maneuver still
allowed NA function and inﬂuenza replication (Marsolais et al., 2009).
GP 33–41 and GP 65–77 incorporated into H1N1 inﬂuenza, when
expressed in infected lung cells and bound to H-2Db or H-2IAb, served
as recognition epitopes for lymphocytes from H-2b transgenic mice
created to express the T cells bearing receptors (TCR) speciﬁc for
these two LCMV immunodominant epitopes. By crossing such TCR
mice with H-2b transgenic mice expressing either GFP or RFP under
transcriptional control of beta actin gene, GFP- or RFP-labeled GP 33
CD8 T cells and GP 65 CD4 T cells allows the isolation of 498% of
GFP- or RFP-labeled LCMV-speciﬁc T cells (Marsolais et al., 2009;
McGavern et al., 2002). 2.5104 of these GFP or RFP labeled LCMV-
speciﬁc CD8 or CD4 T cells were then adoptively transferred into
H-2b (C57Bl/6) naı¨ve adult 8-wk-old mice. One day later 1105 PFUof ﬂu/LCMV recombinant was administered intranasally (Marsolais
et al., 2009). This protocol allows visualization of inﬂuenza virus
replication in the lung by use of immunocytochemistry with speciﬁc
ﬂuoroprobe-labeled antibody to inﬂuenza, in vivo trafﬁcking and
quantitation of inﬂuenza virus-speciﬁc CD8 and CD4 T cells in the
lung and visualization of virus-speciﬁc T cell/inﬂuenza virus-infected
cell interaction (Marsolais et al., 2009; McGavern et al., 2002).
Quantitation of number of CD8 and CD4 virus-speciﬁc T cells is also
measured by FACS providing a complimentary assay. Quantitative
differences between in vivo labeling of T cells and FACS identiﬁcation
assays is less than 10% (McGavern et al., 2002).
Both in vivo trafﬁcking studies and FACS analysis 6 days after
ﬂu/LCMV recombinant virus infection, accumulation of GFP virus-
speciﬁc CD8 T cells and CD4 T cells occurred. The plateau reached
in trafﬁcking virus-speciﬁc T cells occurred between day 6 and 8
post-infection and then dramatically declined at day 10. When
analyzed at day 7 post-infection viral antigen was found through-
out the lung parenchyma. High resolution light microscopy
identiﬁed inﬂuenza antigens in epithelial cells lining bronchioles
and alveolar cells. Inﬁltration of virus-speciﬁc RFP-GP 33 CD8 T
and GFP-GP 65 CD4 T cells was evaluated at day 7 following
intranasal inoculation of ﬂu/LCMV recombinant. Numbers of
trafﬁcking CD8 T cells into the lung was always greater than the
trafﬁcking of CD4 T cells. The ratio of virus-speciﬁc CD8 T cells to
CD4 T cells was 2.6 to 1. In addition, this model also provided the
opportunity to determine if inﬁltrating virus-speciﬁc T cells could
be modulated by chemical probes that would limit the resultant
pulmonary injury mediated by the adoptive immune response.
Since sphingosine-1-phosphate (S1P) receptor agonist have been
reported earlier to sequester lymphocytes in secondary lymphoid
organs and retard their migration to sites of tissue injury (Rosen
et al., 2009, 2007), we turned our attention to beneﬁcial use
of such probes in terms of altering the inﬁltration of virus-speciﬁc
T cells and the outcome of inﬂuenza virus infection.S1P receptor signaling system and effect of S1P receptor agonists
in modulating the adoptive immune response and clinical course
of inﬂuenza virus infection
There are ﬁve speciﬁc S1P receptors that couple to different G
proteins that regulate multiple downstream signaling pathways
(Rosen et al., 2009, 2007). The biologic functions of S1P are
dependent on the cell/tissue location of these receptors and their
relative expression. We began our study for the in vivo inﬂuenza
model using a non-selective S1P receptor pro-drug agonist AAL-R
that signals on receptors S1P1, S1P3, S1P4, and S1P5, but not S1P2
(Fig. 2A) following phosphorylation by sphingosine kinase 2. Local
administration of a single 0.1 mg/kg dose of AAL-R by intratra-
cheal (i.t.) administration when given 2 h (data shown, Fig. 2B,
middle row) or 3 to 4 days (data not shown) after intranasal (i.n.)
infection with 1105 PFU of H1N1 WSN/LCMV signiﬁcantly
down-modulated virus-speciﬁc CD8 T cell accumulation in the
lung whereas administration of vehicle alone (Fig. 2B, top row) or
the chiral enantiomer molecule, AAL-S, that cannot be phosphory-
lated efﬁciently in vivo was unable to restrict T cell inﬁltration
(Fig. 2B, bottom row) into the lung. This assay was performed by
adoptively transferring a pure population (499%) of 5104 GFP-
labeled GP 33 LCMV-speciﬁc T cells 24 h before infection, sacriﬁ-
cing mice 7 days post-infection, isolating T cells from the lung,
gating on GFP and quantitative analysis by FACS. We then
assessed, in other groups of mice treated the same way, the
ability of the remaining virus-speciﬁc T cells to generate a
protective anti-inﬂuenza viral immune response that controlled
and terminated the infection. Administration of AAL-R, which
signiﬁcantly retarded numbers of virus-speciﬁc T cells entering
Fig. 2. The non-selective AAL-R S1P receptor agonist retarded inﬂuenza virus speciﬁc CD8 T cell expansion in inﬂuenza virus infected lungs resulting in signiﬁcant
protection from pulmonary tissue injury and related mortality. Panel A: AAL-R is a non-selective S1P agonist and signals on S1P1, S1P3, S1P4 and S1P5 receptors but not
the S1P2 receptor. Biologic functions of signaling on S1P1, S1P3, S1P4 and S1P5 receptors and their different G protein couplings are displayed. Panel B: AAL-R therapy
signiﬁcantly decreased numbers of inﬂuenza virus speciﬁc CD8 T cells in inﬂuenza virus infected lungs (middle row) compared to controls given vehicle (top row) or the
chiral enantiomer of AAL-R, AAL-S (bottom row). Panel C: signiﬁcant protection from inﬂuenza virus induced death of C57Bl/6 mice treated with AAL-R (yellow color),
compared to vehicle (magenta) treatment. Signiﬁcant protection also followed oseltamivir (blue) therapy when compared to vehicle (magenta). Although AAL-R alone
provided signiﬁcantly greater protection than oseltamivir, the best protection from inﬂuenza infection produced by a lethal challenge with non-mouse passed human
H1N1 2009 (shown) or mouse adapted WSN virus (not shown) came from combined AAL-R with oseltamivir (green) therapy. Panel D complements the mortality graft in
Panel C with histopathologic analysis following treatment with vehicle, AAL-R, oseltamivir or AAL-R combined with oseltamivir. The black bar indicates similar
magniﬁcation for each tissue sample. Greatest degree of hemorrhage and loss of alveolar air space were from vehicleooseltamiviroAAL-RoAAL-Rþoseltamivir.
Representative tissue samples came from over 10 pulmonary sections from four mice in each group. The graph on the right displays outcomes detected in bronchial
washes (BALF) of inﬂuenza virus-infected lung samples after various treatments. Figure adapted from Walsh et al. (2011).
M.B.A. Oldstone et al. / Virology 435 (2013) 92–101 95
M.B.A. Oldstone et al. / Virology 435 (2013) 92–10196inﬂuenza virus-infected lungs, did not alter the immune response
sufﬁciently to alter or raise the viral burden in the lung when
compared to infected mice receiving vehicle or AAL-S. Ten days
after inﬂuenza infection AAL-R, AAL-S and vehicle treated mice all
cleared virus from their lungs. Indeed, AAL-R mice sacriﬁced at
7 days post-inﬂuenza virus challenge showed a robust virus-
speciﬁc CTL response (51Cr release assay) and a vigorous speciﬁc
memory T cell response upon virus stimulation occurred at 40
days post-inﬂuenza virus challenge. Further, the kinetics, titers,
and immunoglobulin subtypes of neutralizing antibodies in sera
of inﬂuenza virus-infected mice treated with AAL-R, AAL-S or
vehicle were equivalent. Taken together these results document
that AAL-R therapy given locally into the respiratory tract down-
modulated the migration of virus-speciﬁc CD8 T cells in the lung.
However, neither inﬂuenza virus replication nor the generation of
protective neutralizing antibodies was adversely effected. Despite
the reduction in numbers of virus-speciﬁc CD8 T cells by AAL-R
activity, inﬂuenza viral infection was still controlled.
Associated with the decreased accumulation of virus-speciﬁc
T lymphocytes in the lung was enhanced survival of mice
receiving a lethal challenge with H1N1 human pandemic 2009
isolate A/Wisconsin/WSLH3439/09 2105 PFU i.n. (data shown,
Fig. 2C), A/California/04/2009 (data not shown), or WSN mouse
adopted virus (data not shown). Neither human H1N1 viruses
isolated from humans had been passaged before in mice. Thus,
while 6 of 28 mice (21%) receiving only vehicle survived i.n.
infection with 2105 PFU of virus, 23 of 28 mice (82%) receiving
AAL-R were protected (Po0.001). Susceptibility and death corre-
lated directly with massive lung consolidation, hemorrhage, and
exudate in lungs of mice receiving vehicle or AAL-S. Signiﬁcantly
less lung pathology occurred in inﬂuenza virus infected mice
receiving AAL-R (Fig. 2D, left panel). Tissue histochemistry and
biochemical analysis of pulmonary exudate (Fig. 2) was done 10
days after initiating the inﬂuenza infection. Quantitation of lung
exudate was by measuring LDH and total protein in the bronchial
lavage ﬂuid (BALF) (Fig. 2D, right panel).
AAL-R also signiﬁcantly down-regulated cytokine/chemokine
synthesis in vivo. Upon inﬂuenza infection there was signiﬁcant
up-regulation of IL-1a, IL-1b, IL-6, IL-10, IL-12, MIP-1, TNF-a,
MIP-1a, GM-CSF, and RANTES in the BALF. IL-6 and MCP-1 levels
were strikingly enhanced similar to reports in both H5N1 infected
humans (de Jong et al., 2006) and 1918–1919 H1N1 infected
macaques (Kobasa et al., 2007) and mice (Kash et al., 2006).
Treatment with AAL-R signiﬁcantly inhibited synthesis of IL-1a,
IL-1b, IL-6, IL-10, MCP-1, TNF-a, and GM-CSF in BALF 2 days post-
infection when compared to mice treated with AAL-S or vehicle.
Cytokine/chemokine suppression was associated with a decrease
of GR-1þ polymorphic leukocytes and F4/80þ macrophages in
the lung which directly correlated with the diminished lung
parenchyma pathology, inﬁltration, and amount of exudate.
Oseltamivir is a potent anti-inﬂuenza drug by its action of
inhibiting the viral neuraminidase. We then tested the therapeutic
potential of an optimal dose of oseltamivir, 5 mg/kg, dissolved in
water administered by gavage for 5 consecutive days starting on
post-infection day 4 alone or in combination with AAL-R to protect
against a lethal challenge of 2105 PFU i.n. of A/Wisconsin/
WSLH34939/09. Vehicle or 0.2 mg/kg of AAL-R was given i.t. 1 h after
virus infection. As shown in Fig. 2C, oseltamivir given alone protected
14 of 28 mice (50%), a result signiﬁcantly improved over vehicle.
However, AAL-R therapy alone provided signiﬁcantly greater
protection than that of oseltamivir (82% vs. 50%). Optimal therapy
occurred when both AAL-R and oseltamivir therapy were combined
as 27 of 28 mice (96%) survived the inﬂuenza infection (Fig. 2C)
(Walsh et al., 2011). Superior survival observed in treatment of
combined AAL-R and oseltamivir, and of AAL-R over oseltamivir
when administered independently closely mirrored the degree ofhistologic evidence of pulmonary injury and degree of exudate in
BALF (Fig. 2D).
The last series in this category investigated the mec-
hanism(s) of how AAL-R impaired the number of virus-speciﬁc
CD8 T cells that trafﬁcked to and deposited in the lung parench-
yma. Upon pulmonary infection, inﬂuenza virus-speciﬁc T cells
are induced and proliferate in mediastinal lymph nodes (MLNs),
then migrate to infected sites in the lung (Baumgarth and Kelso,
1996; Belz et al., 2004). AAL-R signiﬁcantly reduced the numbers
of virus-speciﬁc CD8 and CD4 T cells in MLNs at days 5 and 6
post-infection (Marsolais et al., 2009) and in the lung days 6–8
post-infection indicating that this S1P receptor agonist inhibited
clonal expansion of T cells. Analysis for dead cells (annexin V-
positive virus-speciﬁc T cells) in MLNs and lungs indicated that
these cells were not killed by local respiratory tract therapy with
AAL-R. This result suggested that AAL-R likely altered T cell
stimulation by inﬂuenza virus antigen presenting dendritic cells
(DC) (Allan et al., 2006) rather than by T cell deletion. Study of
AAL-R effect on DCs found that AAL-R did not reduce the numbers
of DCs or their speciﬁc subsets (Marsolais et al., 2009). However,
AAL-R suppressed inﬂuenza virus-induced DC activation in the
lungs and MLNs as measured by reduction in surface expression
of MHC-I, MHC-II, and B7.2 molecules on the DC surfaces. AAL-R
treatment also impaired the stimulatory capacity of DCs as
conﬁrmed by inefﬁcient induction of virus-speciﬁc CD8 T cell
proliferation in vitro (Marsolais et al., 2009). Thus, AAL-R locally
administered in the respiratory tract during inﬂuenza infection
disrupts the antigen-presenting DC network (Steinman and
Hemmi, 2006) by blocking DC-mediated signal transmission from
the infected site to MLNs, leading to a dramatic decrease in T cell
expansion in MLNs and in lungs.
Speciﬁc S1P1 receptor agonists blunt the exaggerated innate immune
host reaction ‘‘cytokine storm’’ by modulating S1P1 signaling
of pulmonary endothelial cells
The non-selective agonist AAL-R reacts by modulating S1P1, 3,
4, 5, and not S1P2 receptors (Rosen et al., 2009, 2007). To
determine if a single or multiple receptors were involved in the
initial cytokine storm and the later immunopathologic adoptive
immune response, discovery and optimization of S1P receptor
subtype selective agonists and antagonists were begun by Hugh
Rosen and colleagues. Further, a variety of genetically engineered
S1P1 receptor knock-out and S1P1 receptor eGFP knock-in mice
were utilized that were physiologically and pharmacologically
normal when compared to wild-type controls. Initially, a series of
well-characterized S1P1 selective agonists were administered
i.t. (CYM-5442: 2 mg/kg; RP-002: 3 mg/kg), or orally (RP-002:
6 mg/kg) (Teijaro et al., 2011). All S1P1 selective agonists provide
protection against a lethal i.n. challenge with human H1N1
A/Wisconsin/WSLH34939 or A/California/04/209 (Fig. 3A) and
blunted cytokine storm (Fig. 3B and C) to a degree equivalent to
that observed earlier with non-selective S1P agonist AAL-R
(Fig. 3D and E). The S1P1 receptor agonists signiﬁcantly inhibited
secretion of cytokines and chemokines associated with inﬂuenza
infection including IFN-a, CCL-2, IL-6, TNF-a, CCL-3, CCL-5, CXCL-2,
IL-1a, and IFN-g. While most of these cytokines/chemokines were
inhibited to a similar degree as with AAL-R therapy, suppression of
CXCL-2, TNF-a, and IFN-g was not as effective, suggesting,
perhaps, a role for other S1P receptor subtypes in modulating
these cytokine/chemokines. In addition, the S1P1 selective ago-
nists signiﬁcantly blunted the accumulation of innate inﬁltration
of macrophages/monocytes (CD11bþ , F480þ , LyG6), neutrophils
(CD11bþ , LyG6þ , F480), and natural killer (NK) cells (NK1.1þ ,
CD3). Further, the expression of the activation marker CD69 was
signiﬁcantly reduced following S1P1 agonist treatment. As with
Fig. 3. Severe inﬂuenza respiratory disease is blunted by S1P1 receptor agonist. Protection by S1P1 speciﬁc receptor agonist is comparable to protection provided by AAL-R
S1P1, S1P3, S1P4, S1P5 receptor agonist. Panels A, B, C: Signiﬁcant protection and ablation of cytokine storm by S1P1 receptor agonist RP-002. Panels D and E: Signiﬁcant
protection by S1P1 receptor agonist CYM-5442 and its comparison to the protection provided by AAL-R agonist to S1P1, S1P3, S1P4 and S1P5 receptor signaling. Figure
adapted from Teijaro et al. (2011), with permission from Elsevier.
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was no increase in viral titers following chemical treatment.
Further, viral infection was effectively terminated and both
humoral (antibody) and cell-mediated (CD8 T cell) arms of the
immune response were generated during S1P1rec agonist ther-
apy. Since cytokine storm, pathologic injury to the lung parench-
yma, and survival of inﬂuenza virus infection were all achieved
with S1P1 agonist therapy, our results implicated S1P1 receptor
signaling as the essential player in the initiation of cytokine storm
and resultant immune-mediated injury. Importantly, our results
also indicated that a severe pulmonary disease associated with
cytokine storm was chemically tractable with a single chemical
molecule, S1P1 agonist that avoided signaling through S1P2, 3, 4,
5 receptors.
Having identiﬁed S1P1rec signaling as the primary pathway
for the initiation of cytokine storm we sought to identify the cell
or cells in the lung that expressed the S1P1 receptor. Since
epithelial cells are the primary cell infected by inﬂuenza virus
we suspected that S1P1 receptor was located on that cell. To
determine the pulmonary cell(s) bearing the S1P1 receptor, we
took advantage of eGFP-S1P1 receptor knock-in mice made by
Stuart Cahalan in the Rosen laboratory (Cahalan et al., 2011). In
this mouse, the native S1P1 receptor was homologously replaced
with a functional fused eGFP-tagged S1P1 receptor (Cahalan et al.,
2011). Utilizing this mouse model we could directly detect eGFP-
S1P1 receptor protein expression of pulmonary cells which we could
then identify by antibodies to speciﬁc pulmonary cell markers and
ﬂow cytometry. Additional conformation was achieved by biochem-
ical analysis of puriﬁed pulmonary cells. High levels of S1P1-eGFP
receptor expression was found on lung lymphatic (CD45 , CD31þ ,
GP38þ) and vascular (CD45 , CD31þ , GP38) endothelial cells but
surprisingly was absent on pulmonary epithelial cells (CD45 ,CD31 , EpCAMþ) (Fig. 4A, top panel). These results were conﬁrmed
by doing Western blots on 498.5% pure populations of pulmonary
endothelial and epithelial cells (Fig. 4C). As expected and previously
reported (19,20), CD4 T cells (CD4þ , CD3þ), CD8 T cells (CD8þ ,
CD3þ), and B cells (B200þ , CD19þ) also expressed S1P1-eGFP
receptor (Fig. 4A). In contrast, pulmonary leukocytes, including
macrophages/monocytes (CD11cþ , CD11b , F480þ), DCs (CD11cþ ,
IA-IEþ , CD205þ , F480), neutrophils, NK cells (NK1.1þ , CD3)
(Fig. 4B), and immature lymphoid cells (LIN , SCA-1þ) failed to
express signiﬁcant levels of eGFP-S1P1 receptor protein. S1P1-eGFP
receptor expression was similar whether cells were harvested from
mice that were uninfected or infected with inﬂuenza virus. Other
experiments in infected mice (Fig. 4C) indicated that S1P1-eGFP
receptor expression is not altered during inﬂuenza virus infection.
Importantly, S1P1 agonist treatment of infected eGFP-S1P1 receptor
knock-in mice did not lessen expression of S1P1-eGFP receptor
indicating that administration of speciﬁc S1P1 agonist does not
degrade the endothelial S1P1 receptor. These results indicated that
functional agonism of S1P1 and not antagonism effect of receptor
degradation is the mechanism by which S1P1 receptor blocking
molecules CYM-5442 and RP-002 suppressed cytokine storm.
T and B lymphocytes as well as pulmonary endothelial cells
are the only ones within the lung that express measurable
amounts of S1P1-eGFP protein (Fig. 4). We therefore determined
whether lymphocytes expressing S1P1 receptor were involved in
S1P1 agonist inhibition of cytokine storm or were merely bystan-
der cells accompanying the innate immune response to inﬂuenza
virus infection. Rag2/ mice are deﬁcient in lymphocytes and
we reasoned that if such inﬂuenza virus infected Rag2/ mice
generated a cytokine storm that could be blocked by S1P1 agonist
then lymphocytes did not contribute to initiation of cytokine
storm and could be excluded as key regulators of inﬂuenza
Fig. 5. Interferon a production is essential to yield the cytokine/chemokine component of cytokine storm. Regulation of innate inﬂammatory cell recruitment into the lung
is also mediated by endothelial cells but is independent of type 1 interferon signaling. Eliminating interferon a occurred by use of inﬂuenza virus infected interferon a–b
receptor knock-out mice. Panel A shows that chemokines/cytokines were signiﬁcantly reduced when interferon a–b sufﬁcient or interferon a–b deﬁcient mice were
treated with S1P1 receptor agonist. In contrast, inﬂammatory cell inﬁltration of macrophages/monocytes, neutrophils and NK cells following S1P1 receptor agonist therapy
were down-regulated only in interferon a–b sufﬁcient mice but not their interferon a–b receptor knock-out counterparts. Figure adapted from Teijaro et al. (2011), with
permission from Elsevier.
Fig. 4. S1P1 receptor is present on pulmonary endothelial cells but not on pulmonary epithelial cells. Panel A identiﬁes S1P1 receptor primarily on pulmonary endothelial
cells, and modestly on CD4 T cells as well as CD8 T cells but not on pulmonary epithelial cells. Panel B displays absence of S1P1 receptor on pulmonary macrophages,
monocytes, dendritic cells, neutrophils or NK cells. Data represented in Panels A and B used eGFP-S1P1 receptor knock in mice, antibodies to speciﬁc markers of various cell
populations and FACS. Cell populations were 498.5% pure. Panel C: Western blotting shows S1P1 receptor primarily on pulmonary endothelial cells but none on
pulmonary epithelial cells. Panel D: Rag2/ knock-out mice do not contain T cells. S1P1 speciﬁc agonist CgM5442 blocked cytokine storm (chemokines/cytokines in
bronchial wash: left panel; and migration of innate inﬂammatory cells: right panel) indicating that the S1P1 receptor agonist acted on pulmonary endothelial cells, not
lymphoid cells to dampen the cytokine storm. Figure adapted from Teijaro et al. (2011), with permission from Elsevier.
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storm occurred in Rag2/ mice infected with inﬂuenza virus and
that treatment with S1P1 agonist CYM-5442 signiﬁcantly reducedcytokines/chemokines (shown IFN-a, CCL-2, IL-6, TNF-a, IFN-g)
and innate inﬁltration of macrophages/monocytes and NK
cells. A further series of experiments conclusively documented
Fig. 6. The alpha-carbon tracing of the S1P1 receptor at 2.8 A˚ resolution. The
orthosteric antagonist ML-056 is fully visualized within the binding pocket
immediately above the rhodopsin GPCR family conserved W269, that serves as a
rotamer toggle switch in rhodopsin, but in S1P1 serves as the binding point of
contact for alternative binding mode agonists like CYM-5442. Extracellular loops
(ECL) 1, 2 and 3 are shown. There are 7
TM
domains and N-term, I, 1st ICL, II, 1st ECL,
III, 2nd ICL, IV, 2 ECL, V, 3rd ICL, VI, 3rd ECL, VII, C-term are shown. V and VI are not
marked in this pose. See Figs. 3–5 for biologic action of the S1P1 agonist CYM-
5442 and Hanson et al. (2012), for additional structural details and amino acid
alignments. Figure adapted from Hanson et al. (2012), reprinted with permission
from AAAS.
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inﬂammatory cell recruitment were independent events that
occurred after inﬂuenza virus infection. However, both cytokine/
chemokine production and innate inﬂammatory cell recruitment
were inhibited by S1P1 receptor agonism of pulmonary endothelial
cells. An important observation is that initial inﬂammatory cell
inﬁltration into the lungs was not dependent or required for
cytokine/chemokine production (Teijaro et al., 2011).
Type I interferon signaling is essential for cytokine/chemokine
response of cytokine storm but is independent of innate inﬂammatory
cell recruitment into the lung
Our observations with inﬂuenza and those of others have
repeatedly documented that type I interferon, predominantly
the IFN-a species, are elevated early after acute respiratory viral
infection. The release and action of type I interferon is believed
crucial for the production of proinﬂammatory cytokines/chemo-
kines. We found that S1P1 receptor agonists inhibited the pro-
duction of IFN-a in the pulmonary parenchyma early after
inﬂuenza infection (Figs. 3 and 4) (Teijaro et al., 2011). To prove
that blunting of IFN-a production was a mechanism by which
S1P1 receptor agonist inhibited cytokine storm, IFNa-brec knock-
out and IFNa-brec sufﬁcient mice infected with 1105 PFU i.n. of
H1N1 virus were treated with S1P1 receptor agonist CYM-5442 or
vehicle and both cytokine/chemokine proteins and innate inﬂam-
matory cell recruitment measured in the bronchial lavage ﬂuid at
48 h post-infection. Cytokines/chemokines IFN-a, CCL-2, IL-6,
IFN-g (shown), CCL-5, and CXCL-10 in the bronchial lavage ﬂuid
were signiﬁcantly reduced in IFNa-brec sufﬁcient and knock-out
mice (Fig. 5A) but inﬂammatory cell inﬁltration of macrophages/
monocytes, neutrophils and NK cells following S1P1 receptor
agonist therapy were only down-regulated in IFNa-b sufﬁcient
and not IFNa-b knock-out mice (Fig. 5B). Thus, regulation of
innate inﬂammatory cell recruitment into lung was mediated by
endothelial cells and was independent of type I interferon
signaling. Cytokine/chemokine production in the lung was also
mediated by endothelial cells but, in contrast, S1P1 receptor
agonism of endothelial cells inhibited IFN-a production leading
to dampening of production of inﬂammatory cytokine/chemokine
responses.Crystal structure of S1P1 receptor complexed with S1P1
receptor antagonist
Recently, Hugh Rosen and Ray Stevens’ laboratories solved the
crystal structure of the lyso-phospholipid sphingosine-1-
phosphate-1 receptor fused to T4 lysozyme in complex with an
antagonist sphingolipid analog ML-056 (W-146) (Hanson et al.,
2012) (Fig. 6). Unique features of the S1P1 receptor were not
predictable from the extensive and rigorous analysis by mutagen-
esis previously performed (Fujiwara et al., 2007, 2005; Inagaki
et al., 2005; Jo et al., 2005; Parrill et al., 2000a, 2000b; Schurer
et al., 2008; Wang et al., 2001). The extracellular face of S1P1
receptor is tightly structured (Hanson et al., 2012) where the
N-terminus a-helix folds over the top of the receptor to block
access to the binding pocket from the aqueous phase. This static
view of the receptor suggests that S1P might require an alternate
route into the binding pocket.
Shown in Fig. 6 is the alpha-carbon tracing of S1P1 receptor at
2.8 A˚ resolution. The orthosteric antagonist ML-056 is fully
visualized within the binding pocket immediately above the
rhodopsin GPCR family conserved W269, which serves as a
rotamer toggle switch in rhodopsin, but in S1P1 serves as the
binding point of contact for alternate binding mode agonists likeCYM-5442. By virtue of these unique interactions with the
receptor, these molecules no longer require the zwitterionic
amino-phosphate headgroup and thus have enhanced physico-
chemical properties that allow delivery to the lung for the
inﬂuenza studies. The crystal structure provides the detailed
insight into molecular interaction that may rationally enhance
the properties of S1P1 agonists for the relief of cytokine storm.Conclusions and future directions
Conclusions reached indicate the following four major points
displayed in tabular form at:1. Cytokine storm plays an essential role in the pathogenesis and
clinical outcome of inﬂuenza virus infection.i. Blockade of cytokine storm provides greater protection than
antiviral therapy to inhibit virus replication and does so
without compromising the host’s ability to control and termi-
nate inﬂuenza virus infection.ii. Observations made with human pathogenic H1N1 Swine 09
inﬂuenza virus isolates and mouse adapted H1N1 inﬂuenza
virus.2. Sphingosine-1-phosphate (S1P) receptor agonists blunts
cytokine storm thus cytokine storm is chemical tractable.i. Blunting of cytokine storm is mediated by just one of the ﬁve
S1P receptors: S1P1.3. Molecular mechanism: S1P1 receptor signaling occurs on
pulmonary endothelial cells and not inﬂuenza virus infected
epithelial cells.i. S1P1 receptor is located on pulmonary endothelial cells and
not on pulmonary epithelial cells.ii. S1P1 agonism suppresses cytokine and innate immune cell
recruitment.4. Immune cell inﬁltration and cytokine production are distinct
events both orchestrated by pulmonary endothelial cells.
M.B.A. Oldstone et al. / Virology 435 (2013) 92–101100i. Proinﬂammatory cytokine responses depend on type I inter-
feron signaling.
A kinetic outline of events of molecular pathogenesis of
inﬂuenza virus infection in the lung leading to cytokine storm
and its resultant morbidity and mortality is sketched as given
below.
Cytokine storm has an early and late stage. The early stage is
reﬂective of a pulmonary endothelial ampliﬁcation network
taking place within the ﬁrst few days of infection. This phase is
mediated by S1P1 signaling on pulmonary endothelial cells. The
second phase of immunopathologic injury and activity occurs
later during inﬂuenza virus infection, days 6–8 post-infection, is
T cell-mediated and signals likely through S1P3, 4, 5rec signaling,
with S1P3rec and S1P4rec the most likely culprits.
Step 1: Inﬂuenza virus enters the upper respiratory tract and
infects primary epithelial cells in the lung parenchyma.
Step 2: Infected epithelial cells produce and release a signaling
molecule(s), not yet deﬁned, that cross-talk with and activate
endothelial cells.
Step 3: Pulmonary endothelial cells augment inﬂuenza virus-
induced cytokine storm by two distinct mechanisms. First,
such non-inﬂuenza virus-infected endothelial cells release a
currently unidentiﬁed molecule(s) that activate primarily
plasmacytoid2 DCs to produce IFN-a.
Step 4: IFN-a production stimulates the expression of proin-
ﬂammatory molecules leading to the initiation of cytokine
storm.
Step 5: The second mechanism by which pulmonary endothe-
lial cells augment inﬂuenza virus-induced cytokine storm is by
attracting the recruitment of innate inﬂammatory cells into
the lung. Such innate inﬂammation inﬁltrates exacerbate
cytokine storm by producing additional proinﬂammatory
molecules.
Step 6: The late stage occurs by day 6–8. Inﬂuenza virus-
speciﬁc T cells activated and expanded in MLN and in pul-
monary tissues produce additional inﬂammatory molecules,
lyse virus-infected epithelial cells and thereby augmenting
cytokine storm and immune-mediated injury.
Future directions include investigating IFN-I as to its cellular
source, species and signaling pathways while dissecting molecu-
lar cross-talk and signaling between pulmonary endothelial cells
and other pulmonary cells, especially inﬂuenza virus infected
epithelial cells and plasmacytoid dendritic cells.
Expansion and generalities of our ﬁndings for other acute
respiratory infections, infectious and autoimmune disorders in
which cytokine storm is a major component. Indeed, preliminary
investigations with Matthew Friedman at the University of Mary-
land Medical School suggest a similar scenario for SARS. Studies
by Kevin Walsh from our laboratory recently found that S1P
agonist successfully aborts pneumonia virus of mice, a murine
model of human respiratory syncytial virus (RSV) disease.3
Additionally, in collaboration with the NIH and Battelle group,
and with Yoshi Kawaoka, we have been studying human patho-
genic H1N1 2009 virus in ferrets, a host whose infection with
inﬂuenza virus is more akin to humans than the mouse. Samples
from infected ferrets not treated; or treated with S1P agonists
only, oseltamivir alone, or S1P agonist combined with oseltamivir
are currently under analysis. Lastly, it is likely that genetic
aberrations in the S1P pathway being uncovered may prove to2 Teijaro, J., H. Rosen, and M.B.A. Oldstone. Unpublished observations, 2012.
3 Walsh, K.B., J.R. Teijaro, M. Welch, and M.B.A. Oldstone. Manuscript sub-
mitted, 2012.be of use for screening and identifying those humans who would
be most susceptible to severe cytokine storm during an inﬂuenza
viral infection. We are currently exploring such genetic proﬁling.Acknowledgments
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